Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 8/2011

01-08-2011 | Original Research Paper

Barrier protective effects of lycopene in human endothelial cells

Authors: Jae Woan Bae, Jong-Sup Bae

Published in: Inflammation Research | Issue 8/2011

Login to get access

Abstract

Aim and objective

Lycopene has antioxidant and anticancer effects but its barrier protective effects and underlying mechanism are not fully identified. The potential barrier protective roles of lycopene in lipopolysaccharide (LPS)-activated primary human umbilical vein endothelial cells (HUVECs) were investigated.

Methods

We determined the barrier protective effects of lycopene, such as permeability, leukocyte adhesion and migration, and activation of proinflammatory proteins in LPS-activated HUVECs.

Results

Lycopene inhibited vascular barrier permeability, expression of cell adhesion molecules, leukocyte adhesion and transendothelial migration in LPS-activated HUVECs. Further studies revealed that lycopene suppressed the production of tumor necrosis factor-alpha (TNF-α) and activation of nuclear factor-κB (NF-κB), CD14 and Toll-like receptor-4 (TLR4).

Conclusion

These findings suggest that lycopene has barrier integrity activity, and inhibitory activity on cell adhesion and migration to endothelial cells by blocking the activation of NF-κB, CD14 and TLR4 expression and production of TNF-α, thereby endorsing its usefulness as therapy for vascular inflammatory diseases.
Literature
1.
Zimmerman GA, McIntyre TM, Prescott SM. Adhesion and signaling in vascular cell–cell interactions. J Clin Invest. 1996;98:1699–702.PubMedCrossRef
2.
3.
Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109:3161–72.PubMedCrossRef
4.
Majno G, Palade GE, Schoefl GI. Studies on inflammation. II. The site of action of histamine and serotonin along the vascular tree: a topographic study. J Biophys Biochem Cytol. 1961;11:607–26.PubMedCrossRef
5.
Hirose R, Katori M. Difference in sensitivity to bradykinin of venules along the vascular trees revealed by changes in vascular permeability. Microcirculation. 1982;2:379–91.
6.
Stewart I, Schluter PJ, Shaw GR. Cyanobacterial lipopolysaccharides and human health – a review. Environ Health. 2006;5:7.PubMedCrossRef
7.
Khachik F, Carvalho L, Bernstein PS, Muir GJ, Zhao DY, Katz NB. Chemistry, distribution, and metabolism of tomato carotenoids and their impact on human health. Exp Biol Med (Maywood). 2002;227:845–51.
8.
Heber D, Lu QY. Overview of mechanisms of action of lycopene. Exp Biol Med (Maywood). 2002;227:920–3.
9.
Nkondjock A, Ghadirian P, Johnson KC, Krewski D. Dietary intake of lycopene is associated with reduced pancreatic cancer risk. J Nutr. 2005;135:592–7.PubMed
10.
Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst. 1999;91:317–31.PubMedCrossRef
11.
Giovannucci E. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp Biol Med (Maywood). 2002;227:852–9.
12.
Khan N, Adhami VM, Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer. 2010;17:R39–52.PubMedCrossRef
13.
Tang X, Yang X, Peng Y, Lin J. Protective effects of lycopene against H2O2-induced oxidative injury and apoptosis in human endothelial cells. Cardiovasc Drugs Ther. 2009;23:439–48.PubMedCrossRef
14.
Rao AV, Agarwal S. Role of antioxidant lycopene in cancer and heart disease. J Am Coll Nutr. 2000;19:563–9.PubMed
15.
Rafi MM, Yadav PN, Reyes M. Lycopene inhibits LPS-induced proinflammatory mediator inducible nitric oxide synthase in mouse macrophage cells. J Food Sci. 2007;72:S069–74.PubMedCrossRef
16.
Zhang LX, Cooney RV, Bertram JS. Carotenoids up-regulate connexin43 gene expression independent of their provitamin A or antioxidant properties. Cancer Res. 1992;52:5707–12.PubMed
17.
Kobayashi T, Iijima K, Mitamura T, Toriizuka K, Cyong JC, Nagasawa H. Effects of lycopene, a carotenoid, on intrathymic T cell differentiation and peripheral CD4/CD8 ratio in a high mammary tumor strain of SHN retired mice. Anticancer Drugs. 1996;7:195–8.PubMedCrossRef
18.
Fuhrman B, Elis A, Aviram M. Hypocholesterolemic effect of lycopene and beta-carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages. Biochem Biophys Res Commun. 1997;233:658–62.PubMedCrossRef
19.
Saedisomeolia A, Wood LG, Garg ML, Gibson PG, Wark PA. Lycopene enrichment of cultured airway epithelial cells decreases the inflammation induced by rhinovirus infection and lipopolysaccharide. J Nutr Biochem. 2009;20:577–85.PubMedCrossRef
20.
Herzog A, Siler U, Spitzer V, Seifert N, Denelavas A, Hunziker PB, et al. Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J. 2005;19:272–4.PubMed
21.
Reifen R, Nur T, Matas Z, Halpern Z. Lycopene supplementation attenuates the inflammatory status of colitis in a rat model. Int J Vitam Nutr Res. 2001;71:347–51.PubMedCrossRef
22.
Bae JS, Kim YU, Park MK, Rezaie AR. Concentration dependent dual effect of thrombin in endothelial cells via Par-1 and Pi3 Kinase. J Cell Physiol. 2009;219:744–51.PubMedCrossRef
23.
Bae JS, Rezaie AR. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost. 2008;100:101–9.PubMed
24.
Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993;92:1866–74.PubMedCrossRef
25.
Wung BS, Ni CW, Wang DL. ICAM-1 induction by TNFalpha and IL-6 is mediated by distinct pathways via Rac in endothelial cells. J Biomed Sci. 2005;12:91–101.PubMedCrossRef
26.
Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508–19.PubMedCrossRef
27.
Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev. 2003;83:1069–112.PubMed
28.
Javaid K, Rahman A, Anwar KN, Frey RS, Minshall RD, Malik AB. Tumor necrosis factor-alpha induces early-onset endothelial adhesivity by protein kinase Czeta-dependent activation of intercellular adhesion molecule-1. Circ Res. 2003;92:1089–97.PubMedCrossRef
29.
Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431–3.PubMedCrossRef
30.
Partridge CA, Horvath CJ, Del Vecchio PJ, Phillips PG, Malik AB. Influence of extracellular matrix in tumor necrosis factor-induced increase in endothelial permeability. Am J Physiol. 1992;263:L627–33.PubMed
31.
Garcia JG, Verin AD, Schaphorst KL. Regulation of thrombin-mediated endothelial cell contraction and permeability. Semin Thromb Hemost. 1996;22:309–15.PubMedCrossRef
32.
Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394–7.PubMedCrossRef
33.
Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med. 1999;189:615–25.PubMedCrossRef
34.
Kitchens RL. Role of CD14 in cellular recognition of bacterial lipopolysaccharides. Chem Immunol. 2000;74:61–82.PubMedCrossRef
35.
De Nardin E. The role of inflammatory and immunological mediators in periodontitis and cardiovascular disease. Ann Periodontol. 2001;6:30–40.PubMedCrossRef
36.
Hopkins SJ. The pathophysiological role of cytokines. Leg Med (Tokyo). 2003;5(Suppl 1):S45–57.
37.
Lacasse C, Turcotte S, Gingras D, Stankova J, Rola-Pleszczynski M. Platelet-activating factor stimulates interleukin-6 production by human endothelial cells and synergizes with tumor necrosis factor for enhanced production of granulocyte-macrophage colony stimulating factor. Inflammation. 1997;21:145–58.PubMedCrossRef
38.
Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004;24:2137–42.PubMedCrossRef
39.
Li Y, Schwabe RF, DeVries-Seimon T, Yao PM, Gerbod-Giannone MC, Tall AR, et al. Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: model of NF-kappaB- and map kinase-dependent inflammation in advanced atherosclerosis. J Biol Chem. 2005;280:21763–72.PubMedCrossRef
40.
Stoll LL, Denning GM, Weintraub NL. Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease. Curr Pharm Des. 2006;12:4229–45.PubMedCrossRef
41.
Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001;276:11199–203.PubMedCrossRef
42.
Joyce DE, Grinnell BW. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med. 2002;30:S288–93.PubMedCrossRef
43.
Takeda R, Suzuki E, Satonaka H, Oba S, Nishimatsu H, Omata M, et al. Blockade of endogenous cytokines mitigates neointimal formation in obese Zucker rats. Circulation. 2005;111:1398–406.PubMedCrossRef
44.
Feng D, Ling WH, Duan RD. Lycopene suppresses LPS-induced NO and IL-6 production by inhibiting the activation of ERK, p38MAPK, and NF-kappaB in macrophages. Inflamm Res. 2010;59:115–21.PubMedCrossRef
45.
Joo YE, Karrasch T, Muhlbauer M, Allard B, Narula A, Herfarth HH, et al. Tomato lycopene extract prevents lipopolysaccharide-induced NF-kappaB signaling but worsens dextran sulfate sodium-induced colitis in NF-kappaBEGFP mice. PLoS One. 2009;4:e4562.PubMedCrossRef
Metadata
Title
Barrier protective effects of lycopene in human endothelial cells
Authors
Jae Woan Bae
Jong-Sup Bae
Publication date
01-08-2011
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 8/2011
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-011-0330-9

Other articles of this Issue 8/2011

Inflammation Research 8/2011 Go to the issue

Short Communication

The hippocampal fimbria of cuprizone-treated animals as a structure for studying neuroprotection in multiple sclerosis

Original Research Paper

Lipopolysaccharide and platelet-activating factor stimulate expression of platelet-activating factor acetylhydrolase via distinct signaling pathways

Original Research Paper

G1 cell cycle arrest signaling in hepatic injury after intraperitoneal sepsis in rats

Original Research Paper

Simplified detection of eosinophils in induced sputum

Original Research Paper

Mimic peptides bonding specifically with the first and second extracellular loops of the CC chemokine receptor 5 derived from a phage display peptide library are potent inhibitors of experimental autoimmune encephalomyelitis

Original Research Paper

Potential role of NADPH oxidase-mediated activation of Jak2/Stat3 and mitogen-activated protein kinases and expression of TGF-β1 in the pathophysiology of acute pancreatitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits